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Sentinel lymph node procedures for gastric cancer resections using indocyanine
green (ICG) linked to Nanocoll outperformed normal ICG but did not provide
information on possible lymph node metastasis. Carcinoembryonic antigen targeted
fluorescent imaging using SGM‐101 was successful in both pancreatic and colorectal
cancer. A large phase III multicentre trial will soon be initiated in colorectal cancer
patients.
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1 | FLUORESCENT‐GUIDED SURGERY
Intraoperative discrimination between benign and malignant tissue is
primarily based on tactile and visual examination by surgeons. Both
of these subjective methods have limitations in assessing tumor
margins. As a result, positive resection margins still regularly occur
with local recurrence and metastases as likely consequences.
Near‐infrared (NIR) photons can penetrate deeply into tissue (up
to 5 to 10mm). This is utilized by NIR fluorescence (NIRF) to provide
fast and quantitative contrast images.1,2 Fluorophores can either
accumulate in tumor tissue due to either the enhanced permeability
and retention (EPR) effect or by targeting a specific tumor marker.
Once activated by laser, NIRF light reflected by the fluorophore can
be visualized using a dedicated imaging system. NIRF‐guided surgery
can help distinguish benign from malignant tumor tissue and also aid
in identifying lesions or metastasis outside the standard field of
resection3 and therefore might influence clinical decision making.
Recently, research has shifted from nonspecific imaging (depending
on the EPR effect) toward tumor‐marker specific imaging (eg, tumor
receptor targeting). NIRF imaging is currently being investigated for
multiple purposes in clinical trials. This review discusses two applications
of targeted and nontargeted NIRF. First, the clinical and preclinical data
on NIRF‐guided sentinel lymph node (SLN) identification in gastric cancer
using indocyanine green (ICG) is discussed. Subsequently, the available
data on carcinoembryonic antigen (CEA) targeted NIRF imaging in rectal
and pancreatic cancer is reviewed.
2 | SLN IDENTIFICATION IN GASTRIC
CANCER
Tumor resection is imperative when treating gastric cancer with curative
intent. In addition to total or partial gastric resection, a standardized
lymph node dissection is performed. Lymph node metastasis in gastric
cancer patients is an established prognostic factor for survival. Lymph
node involvement is found in 2% to 50% of patients, increasing with
tumor stage.4 Currently, a fixed number of lymph nodes is resected,
regardless of the presence of lymph node metastases. However, since
extensive (D2) lymph node dissection is associated with higher morbidity
(eg, anastomotic leakage) and mortality compared to D1 lymph node
dissection, futile D2 lymphadenectomy in patients without metastatic
lymph nodes is unfavorable.5,6 Possibly, a SLN procedure could avoid
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unnecessary lymph node dissection. During a SLN procedure only the
primary draining lymph nodes (which are at the highest risk of containing
tumor metastases) are identified and dissected. Whereas histological
assessment on hematoxylin and eosin (H&E) stained slides can accurately
identify metastases for most cancer types, it has been shown that
absence of visible tumor cells on H&E slides of gastric cancer lymph
nodes does not guarantee absence of micrometastases.7-11 To overcome
this diagnostic challenge, additional examination (eg, immunohistochem-
istry) is used to detect micrometastases.12 Although several techniques
are available, they are expensive and time‐consuming.13
Multiple trials have been performed to investigate methods of
SLN detection and showed accuracy rates up to 99% when detecting
lymph nodes with a dual tracer consisting of radiolabeled tin colloid
and blue dye.14 This dual tracer provides the surgeon with visible
blue dye and audible guidance based on radioactivity measured by a
handheld probe. However, the disadvantage of this technique is
irreversible hampering of the operating field by the blue dye.
Intraoperative NIRF can also be used to identify draining lymph
nodes in real time. In contrast to the blue dye, NIRF does not alter
the operating field by dark staining and allows detection of deeper
situated nodes.
The concept of using NIRF for the identification of draining lymph
nodes in gastric cancer was first described by Soltesz et al
(preclinical) and Kusano et al (clinical).15,16 In the first study,
fluorescent quantum dots were used in animal experiments and
showed successful lymph node detection. The second study
described the first inhuman trial using ICG (a cyanine dye which
passively accumulates in tumor areas due the EPR effect, with its
emission peak at 800 nm) and showed safe and accurate identifica-
tion of gastric sentinel lymph nodes. Since the success of these
studies, numerous other trials have proven the feasibility and safety
of this method. However, more false‐positive lymph nodes were
found than anticipated due to spread of the contrast agent through
lymphatic vessels to second‐tier lymph nodes.17-21 Hence, no
additional value of the NIRF was observed, since still too many
lymph nodes were unnecessarily resected.22
To overcome this problem of migration to second‐tier lymph
nodes, Tummers et al suggested using ICG adsorbed to nanocolloid.23
This principle was first described in breast cancer and skin melanoma
studies.24,25 The adsorption of nanocolloid to ICG increases its
hydrodynamic diameter from <1 nm to 20 to 80 nm. Only molecules
with a hydrodynamic diameter of <10 nm can migrate to second‐tier
lymph nodes.26 In this way, spreading of ICG to second‐tier lymph
nodes can be retained.23
The study by Tummers et al assessed the feasibility of ICG:Nanocoll
for the identification of sentinel lymph nodes in gastric cancer and also
investigated the prognostic utility of the detected sentinel lymph
nodes.23 ICG:Nanocoll was injected intraoperatively into four quadrants
of the tumor after which fluorescent imaging was performed.
In this study included 22 gastric cancer patients, with varying
tumor stages, undergoing partial or total gastrectomy were assessed.
In 21 out of 22 patients, at least one fluorescent lymph node was
visualized and a mean number of 3.1 (range 1 to 6) lymph nodes were
detected. This is significantly lower compared to earlier reported
means of 7.2 and 9.3 when using ICG alone.17,20 The mean tumor‐to‐
background ratio (TBR, strength of fluorescent signal in tumor
divided by signal strength of background) was 4.4. Histological
examination showed lymph node metastases in 8 out of 21 patients.
In six out of these eight patients, metastatic lymph nodes could be
detected with the fluorescent signal. Nonfluorescent metastatic
lymph nodes (n = 7) were found in the other two patients. All
7 nonfluorescent metastatic lymph nodes, however, were completely
obliterated by tumor tissue. This suggests that lymphatic functions
such as lymph flow or drainage were hampered, and the fluorescent
agent was not able to reach the lymph nodes. In eight patients, the
initial treatment plan was altered based on fluorescent lymph nodes
found outside of the standard resection plane. In two out of these
eight patients, the additional lymph nodes were tumor positive.
Tummers et al conclude that NIRF can aid in identifying
additional draining lymph nodes outside of the standard plane of
resection (eg, skip metastasis in extraperigastric lymph nodes, which
are found in up to 11% of patients) similarly to previous studies
performed in breast cancer patients.24,27,28
Recent studies have indicated that sentinel node biopsy is most
relevant in early gastric cancer cases since this subset of patients have
low chances of lymph node metastasis.29-31 A recent study by Kinami
et al has demonstrated the feasibility of this technique in q72 early
gastric cancer cases specifically, using ICG.32 Only one false‐negative
case was observed, which was due to failure of frozen section diagnosis.
It still remains unclear if the use of ICG in SLN procedures has
additional value, since it does not give any information on the
presence of micrometastases in identified draining lymph nodes.
Possibly, tumor‐marker targeted NIRF could assist in this matter. An
overview of the mentioned clinical studies is depicted in Table 1.
3 | TARGETED FLUORESCENT ‐GUIDED
SURGERY AND RATIONALE FOR CEA
IMAGING
Since nontargeted fluorophores such as ICG, have limited applic-
ability in specifically delineating tumor tissue, the era of receptor‐
targeted fluorescent‐guided surgery has commenced.34 For this
purpose, highly overexpressed tumor markers are required, that
are not (or minimally) expressed on normal tissue. CEA is such a
molecular marker. CEA is present on embryonic cells and highly
expressed by many cancer types including pancreatic ductal
adenocarcinoma (PDAC), colorectal cancer (CRC), and gastric cancer.
CEA is also expressed under inflammatory conditions. Overexpres-
sion of CEA on tumor tissue is seen in over 90% of all CRC and PDAC
patients.35-37 After production and attachment to the cell membrane,
CEA is shed into the bloodstream and is therefore a measurable
protein in serum. Serum CEA is the only tumor marker that has
shown to efficiently monitor therapy response in CRC patients.
Consequently, monitoring of serum CEA during follow up has become
standard of care.38
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Since CEA is highly expressed by many tumor types and absent
on healthy tissue, it could serve as a target for tumor‐specific imaging
and therapy. Previous research has already investigated CEA as a
target for therapy of solid tumors including T cell‐specific antibodies
and radioimmunotherapy.39-41
An imaging modality in which CEA could be used as a target is
fluorescence‐guided surgery. Recently, SGM‐101, a CEA‐targeted
fluorescent probe (emission peak at 700 nm) was developed
(SurgiMab, Montpellier, France) and is currently being tested in
clinical trials.42 The BM104 dye (a fluorescent carbocyanine dye)
was conjugated to an anti‐CEA chimerized monoclonal antibody
and extensive preclinical research has been performed.42 Other
CEA‐targeted fluorescent probes have been developed and tested
preclinically although they have not been used in‐human clinical
trials yet.43-46 Boonstra et al46 have successfully developed a
CEA‐targeting fluorescent probe using single‐chain antibody
fragments (ssSM3E/800CW), but have not translated this into
clinical trials. DeLong et al45 have developed anti–CEA‐IR-
Dye800CW. However, this was also only tested in mouse models
so far. SGM‐101 was first evaluated in mouse models with
peritoneal carcinomatosis. This study showed that SGM‐101
allowed identification and resection of very small tumors that
would otherwise not have been detected.42 Next, experiments
using SGM‐101 in orthotopic colon cancer grafts, liver metas-
tases, and pancreatic tumor cell xenografts were performed.42 All
three experiments showed great promise in detecting and
demarcating tumor nodules that were previously not visible.
Histological assessment of tumor tissue showed colocalization of
tumor cells and fluorescent signal.
Currently, there are two ongoing clinical trials using SGM‐101.
The first is performed by our group (Clinicaltrials.gov:
NCT02973672). SGM‐101 is administered 2 to 6 days before surgery
with a dose escalation of 5 to 15mg in patients with pancreatic
cancer, primary CRC, recurrent rectal cancer or colorectal peritoneal
metastases. The second trial includes patients with peritoneal
carcinomatosis from digestive cancers (FLUOCAR‐1 trial) and is
performed by the group of Dr Francois Quenet in Montpellier, France
(Clinicaltrials.gov: NCT02784028). In this trial, SGM‐101 is adminis-
tered 1 to 2 days before surgery with a dose escalation of 5 to 15mg.
The main goal of this study is to determine the optimal dose for
phase II studies.
4 | CEA AND CRC
The cornerstone of CRC treatment is resection of the tumor with
clear margins (R0 resection). Despite neoadjuvant treatment proto-
cols for rectal cancer, up to 17.2% of rectal cancer patients and 5.3%
of colon cancer patients still have positive resection margins
(R+).47,48 In rectal cancer patients with threatened or involved
circumferential resection margins, R1 resections are seen in up to
25% of the patients.49,50 Positive resection margins are correlated
with higher rates of local recurrence (up to 40%) and worse disease‐
free and overall survival.51-53
CEA serum measurements are currently used during follow‐up
and can indicate local recurrence or metastatic disease when values
are rising.38 Interestingly, a recent histopathological study by
Boogerd et al54 showed lack of correlation between serum CEA
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TABLE 1 Overview of clinical trials and their main outcomes
Author Patients Main outcomes
Sentinel lymph node navigation using ICG in gastric cancer
Kusano et al16 22 The detection rate, accuracy, and false‐negativity rates were 90.9%, 88.9%, and 33.3% in T1 stage
patients, but lower in higher tumor stages. A mean of 3.6 nodes per patients was detected.
Lee et al87 22 The sensitivity, specificity, and false‐negativity were respectively 100%, 94.4%, and 0.0%.
Tajima et al20 56 A mean of 7.2 sentinel nodes was found. A higher accuracy rate was established in T1 stage cancers
compared to higher tumor stages.
Yano et al88 130 All (100%) lymph nodes were identified and 100% sensitivity was established using ICG. All
metastatic lymph nodes were fluorescent.
Kinami et al32 72 The sensitivity, specificity, and accuracy of ICG sentinel node mapping were, respectively, 90.1%,
100%, and 98.6%. A median of six fluorescent nodes was found.
Tummers et al23 22 Sentinel nodes outside the standard plane of resection were identified using ICG:Nanocoll. In 8 of
22 patients, the initial treatment plan was altered based on the fluorescent imaging.
CEA‐targeted fluorescent‐guided surgery in colorectal and pancreatic cancer
Boogerd et al33 26 Optimal dosing was set at 10mg of SGM‐101, best imaged 96 hours postinjection. Primary cohort:
seven of nine colorectal tumors visualized using fluorescence (two nonfluorescent lesions were
pathological complete responders).
Expansion cohort: in 6 of 17 patients the treatment strategy was altered based on fluorescence.
Sensitivity 98%, specificity 62%, and accuracy 84%.
Hoogstins
(unpublished data)
12 Optimal dosing was set at 10mg of SGM‐101, best imaged 96 hours postinjection. All pancreatic
tumors were visible using NIR fluorescence, with a mean TBR of 1.6. Also all four metastatic lesions
were visible using NIR fluorescence.
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and tumor CEA expression in rectal cancer. Most important for
fluorescent‐guided surgery, a great difference is seen in expression
levels of CEA between CRC tissue and healthy tissue (60‐fold).55 The
antigenic density of CEA on CRC cells is 105 to 106 antigens per cell.
Synchronous peritoneal metastases are seen in 4.3% of primary
CRC patients, and in 20% to 50% of patients with recurrent
CRC.56-61 With the introduction of cytoreductive surgery (CRS)
in combination with hyperthermic intraperitoneal chemotherapy,
overall median survival has risen from 12 to 32 months.62 Since the
peritoneal cancer index and the extent of resection in CRC are
associated with survival, maximal resection of all peritoneal cancer
tissue is crucial.63 As fluorescent‐guided surgery can detect (often
small) metastatic nodules, it could help detect and resect metastatic
disease, thereby increasing local control and survival.
The combination of a good level of contrast between healthy and
cancer tissue and high antigenic density makes CEA an excellent
candidate for fluorescent‐guided surgery in CRC. Furthermore, CEA
expression does not seem to alter after neoadjuvant therapy.64
Several CEA‐targeting fluorescent probes have been tested
preclinically in colon cancer models. Anti–CEA‐IRDye800CW has
been tested by DeLong et al45 in orthotopic mouse models injected
with HT‐29 colon cancer cells. This study demonstrated effective
labeling of CEA‐expressing human colon cancer in mouse models
during laparotomy at both 24 and 48 hours after injection. Boonstra
et al46 developed a single‐chain antibody fragment (ssSM3E/800CW)
to visualize CRC lesions. Animal experiments showed a mean TBR of
2.37 at 24 hours postinjection, which is sufficient for clear identifica-
tion of tumor tissue. At histological assessment, CEA expression
clearly correlated with the NIRF signal using light and fluorescence
microscope.
SGM‐101 is a clinically translated fluorescent agent targeting
CEA. Recently, Boogerd et al33 have published the first in‐human
clinical trial with CEA‐targeted fluorescent‐guided surgery in CRC
patients. This study assessed the tolerability and pharmacokinetics of
ascending doses of SGM‐101 and determined the optimal dose and
timing for fluorescent‐guided surgery (10mg, 96 hours postinjection).
In the primary cohort seven of nine tumors showed in vivo or ex vivo
fluorescent signal (mean TBR 1.8). The two nonfluorescent rectal
tumors were confirmed as pathological complete responders, thus no
tumor tissue was present. An expansion cohort of 17 patients with
recurrent rectal cancer or peritoneal metastasis of CRC was set up.
In 6 of 17 patients, the original treatment strategy was altered based
on fluorescent imaging findings. It was concluded that SGM‐101
showed a sensitivity of 98%, specificity of 62% and an accuracy of
84% in detecting rectal cancer. Figure 1 shows the ex vivo
fluorescence imaging of a recurrent rectal tumor using SGG‐101.
CEA‐targeted fluorescent‐guided surgery could aid in better
resection of primary colorectal tumors, colorectal recurrence, and
metastases (eg, liver, lung, peritoneal). Particularly in local recurrent
rectal cancer, fluorescent‐guided surgery could be useful since
distinguishing fibrosis from tumor tissue can be challenging. Also,
during the follow up period after CRC surgery, tumor‐targeted
fluorescent imaging could be of additional value. Currently, conven-
tional endoscopy is used to assess the anastomosis and possible other
newly developed or missed tumors. Fluorescent‐guided endoscopy
could possibly better indicate tumor remnants or local regrowth.
Fluorescent‐guided endoscopy targeting VEGF (bevacizumab) and
c‐Met is currently being investigated in clinical trials at the University
Medical Centre Groningen in The Netherlands (Clinicaltrials.gov:
NCT03205501).65,66 CEA also shows great promise to be a successful
imaging target for endoscopy. For example, in patients with a clinical
complete response (cCR) after neoadjuvant chemoradiotherapy in
whom surgery is omitted and are followed in a Watch‐and‐Wait
protocol. In the same way, CEA‐targeted positron emission tomo-
graphy (PET) imaging could aid in detecting tumors. By targeting
tumor cells, the radioactive signal could indicate remaining or
recurrent tumors. This concept is already routinely performed in
prostate cancer with a prostate‐specific membrane antigen PET tracer
but could also be useful in CRC cancer staging and follow up using a
CEA‐targeted tracer.
5 | CEA AND PANCREATIC CANCER
Compared to the relative good overall survival of CRC cancer
patients, pancreatic cancer still has a dismal prognosis. Pancreatic
cancer accounts for 7% of all cancer related deaths in the United
States, with the vast majority of neoplasms being PDACs.67 The
overall 5‐year survival rate is 8%, whereas patients diagnosed with
metastatic disease only have a 3% five‐year survival rate.67,68 The
ESPAC‐4 trial underlines the importance of radical resection of
pancreatic cancer considering the median overall survival time of
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F IGURE 1 Ex vivo fluorescence imaging of a recurrent rectal tumor using SGM‐101 (injected 4 days before surgery, 10mg). The remaining
fluorescence (arrow) was confirmed tumor‐positive. Color (left column), fluorescence (middle column), and merged (right column) images [Color
figure can be viewed at wileyonlinelibrary.com]
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39.5 months after R0 resection versus 23.7 months after R1
resection (both observed in patients treated with adjuvant gemcita-
bine plus capecitabine).69 For the eligible patients, pancreatic
resection is associated with serious morbidity (eg, pancreatic fistula
and hemorrhage; 19.9%), perioperative mortality (2%) and up to 30%
disease‐related mortality in the first year after resection.70-73 CT is
the preferred modality and has shown to be able to predict
resectability in >75% of patients.74 Intraoperative distinction
between normal (often inflamed) tissue and tumor tissue is
challenging, resulting in up to 70% irradical resections.75 CT is
insufficient in detecting tumor downstaging after neoadjuvant
therapy and is also inadequate in distinguishing viable tumor cells
from scar tissue. Thus, neoadjuvant treatment can complicate the
assessment of resectability on CT even more.76,77
Amongst others, fluorescent‐guided surgery could potentially aid
in distinguishing noncancerous pancreatic tissue from tumor tissue
and thus might lead to a higher rate of radical resections, resulting in
increased overall survival. Additionally, this method could help
identify (occult) metastases during staging laparoscopy.78 The role
of staging laparoscopy is currently under debate, since only 15% to
51% of occult metastasis cases can be identified using this
modality.79 A study investigating staging laparoscopy using con-
trast‐enhanced ultrasound and fluorescence (ICG) has been per-
formed by our group.80 Twenty‐five patients were included in this
study. Patients received 10mg of ICG 1 day prior to surgery to
detect possible liver metastases. Intraoperative fluorescence imaging
and laparoscopic ultrasound of the liver were performed. Of every
lesion suspect for metastasis a biopsy or resection was performed.
This study concluded that intraoperative use of ultrasound has
limited value. However, laparoscopic fluorescence imaging using ICG
showed the highest accuracy in detecting liver metastases compared
to inspection and laparoscopic ultrasound.
The concept of fluorescent‐guided surgery in pancreatic cancer
has already been tested with ICG. Unfortunately, insufficient
contrast between benign and malignant tissue was achieved and no
additional value of optical fluorescent‐guided surgery was found.81
In search of other tumor‐specific imaging targets, de Geus et al
found that CEA, integrin αvβ6, epithelial growth factor receptor and
urokinase plasminogen activator receptor seem suitable targets for
pancreatic imaging.82 In this study, 158 of 165 (96%) of pancreatic
and periampullary adenocarcinomas could be identified using CEA
immunohistochemistry.
Tummers et al83 observed membrane‐bound, heterogeneous
expression of CEA in PDAC and a significantly lower expression on
chronic pancreatitis compared to PDAC. CEA is present in PDAC, but
not in normal acini and healthy pancreatic tissue. Unfortunately, loss
of expression after neoadjuvant treatment was seen and is
disadvantageous since no distinction between vital and necrotic
tumor tissue can thus be made after neoadjuvant treatment based on
CEA expression.83
As mentioned before, SGM‐101 is also being investigated for
intraoperative imaging in pancreatic cancer patients. Gutowski et al42
showed that in orthotopic mouse models injected with BxPC3 cells
(pancreatic cancer), SGM‐101 showed clear tumor delineation with a
TBR of 3.5. Experiments using other CEA‐targeted fluorescent agents
(anti–CEA‐Alexa Fluor 488) on BxPC3 cells in mouse models were
performed by Metildi et al84 and Cao et al.85 In these studies,
fluorescent‐guided surgery resulted in less tumor recurrence
(P = 0.01), higher cure rates (45% vs 40%, P = 0.01) and higher
1‐year survival rates (0% vs 28%, P = 0.01) when compared to
conventional bright light surgery.
Following the successful preclinical experiments, our group included
12 PDAC patients in a clinical trial (Clinicaltrials.gov: NCT02973672,
Hoogstins, unpublished data). No clear difference was observed in TBR
between the three dosing groups and 96hours postinjection was
established as the preferred time of imaging. The study demonstrated
that the use of SGM‐101 in pancreatic cancer patients is safe. All tumors
were visible with intraoperative fluorescent imaging, with a mean TBR of
1.6 in primary tumors and 1.7 in metastatic lesions. All metastatic lesions
(three liver and one peritoneal metastasis) were visible using fluores-
cence. Additionally, eight nonfluorescent but clinically suspect lesions
(not primary tumors) were resected, of which two contained tumor cells.
Of the initial 12 patients, in five patients the resection was
abandoned due to irresectability or metastases. These five patients
also had higher serum CEA levels preoperatively. This possibly
indicates a predictive role for CEA in resectability of pancreatic
tumors.
The TBR as seen in intraoperative setting was significantly lower
than expected from the mouse models (TBR 3.5). A possible
explanation for this can be the poor vascularization of pancreatic
tumors and presence of desmoplastic stroma in pancreatic tumors,
resulting in poor delivery of SGM‐101.86 However, the fact that
fluorescent signal was observed in most patients demonstrates that
the contrast agent was undoubtedly able to reach the tumor cells.
The limitations of this “far red” part of the NIR spectrum are more
autofluorescence and lower depth penetration compared to the
higher NIR wavelengths.89
Currently, fluorescent agents targeting the endothelial growth
factor receptor and the vascular endothelial growth factor (VEGF;
PENGUIN trial) are also being clinically tested for pancreatic cancer
imaging (Clinicaltrials.gov: NCT03384238, NCT02743975).
6 | DISCUSSION
This review outlines the available literature on SLN procedures in
gastric cancer using ICG and provides an overview of CEA‐targeted
NIRF imaging. An SLN procedure using ICG:Nanocoll has shown to be
feasible and safe; however, the clinical applicability is still unclear.
Only one CEA‐targeted NIRF agent, SGM‐101, has yet been tested in
clinical trials. Successful studies using SGM‐101 have been described
in pancreatic cancer, CRC, and peritoneal metastasis of digestive
cancers.
The use of fluorescence imaging with ICG during SLN procedures
in gastric cancer remains controversial. Since no specific receptor
target is used, the fluorescent signal is not specific for lymph node
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metastases. As shown by Tummers et al23 distinguishing tumor‐
positive lymph nodes from tumor negative lymph nodes is impossible
using ICG:Nanocoll. Also, as discussed above, completely obliterated
lymph nodes cannot be reached with ICG and are thus not visible
with fluorescence, underlining the need for tumor‐specific fluores-
cent tracers.
During CRC surgery intraoperative fluorescence imaging was
successful. Definitely, in the expansion cohort with recurrent rectal
cancer and peritoneal metastasis of rectal cancer, an additional value of
SGM‐101 has been observed. Following the recent successful trial with
SGM‐101 in CRC, a multicentre, phase III clinical trial will soon be
initiated. A large cohort of CRC patients will be included in up to
10 centers in Europe and the United States. The rationale for this study is
that SGM‐101 fluorescence imaging can offer clear delineation of tumor
masses, identify subclinical carcinomatosis or aid in the assessment of
residual disease and thus lead to more radical resections with hopefully
less local recurrence or metastatic disease.
Furthermore, CEA‐targeted imaging could be helpful during the
follow up of rectal cancer patients with a cCR after neoadjuvant
chemoradiotherapy. Patients with a cCR might enter a follow‐up
period of watchful waiting (in clinical studies) and surgery will be
omitted. Considering that only vital tumor cells express CEA, CEA‐
targeted fluorescent signals in routine follow up endoscopy could
show remaining tumor cells after therapy or local regrowth during
follow up.
In spite of the poor vascularization and presence of stroma in
PDAC, molecular imaging of PDAC targeting CEA was feasible. The
fluorescent signal was observed in all pancreatic tumors. This study
demonstrates the feasibility of antibody‐targeted fluorescent ima-
ging using SGM‐101 in pancreatic cancer. Considering the much
higher TBR’s measured ex vivo versus in vivo, there might be a need
for more sensitive intraoperative imaging systems. In addition to
CEA, integrin αvβ6 also shows great promise for targeted imaging
and will be investigated for both optical fluorescence and PET tracer
purposes by our group. Possible applications for tumor‐targeted
pancreatic imaging could be in detecting primary and metastatic
disease, but also in assessing vascular involvement. Particularly after
neoadjuvant chemotherapy, NIRF could aid in distinguishing che-
motherapy induces fibrosis from viable tumor tissue.
Because CEA expression on the cell surface of tumors is variable,
patient selection before surgery would be beneficial. However, since
Boogerd et al54 described a lack of correlation between tumor CEA
expression and serum CEA levels in rectal cancer, serum CEA levels
seem inadequate for patient selection. In contrast to rectal cancer,
the study did find a significant correlation between serum CEA and
the percentage of CEA‐expressing tumor cells in PDAC patients.
A possible explanation for this could be the different vascularization
of both tumor types (rectal tumors are usually well vascularized
whereas pancreatic tumors show poor vascularization and drug
delivery). In PDAC however, predicting CEA tumor expression using
serum CEA levels seems to be more accurate.
In addition to the described CEA‐targeted antibody, various other
methods of tumor targeting are available. Specific targeting using smaller
tumor‐targeting particles (eg, nanobodies, antibody fragments, peptides)
can increase tumor specificity and enable injection at the day of surgery.
When combining this with a fluorophore emitting light at higher
wavelengths, lower background signal could be achieved.
In conclusion, this review shows that SLN procedures for gastric
cancer resections using ICG:Nanocoll outperformed procedures
using normal ICG. However, the clinical relevance can be argued
since the fluorescent signal only indicates lymph node presence, but
gives no information as for the presence of lymph node metastasis.
Tumor‐specific targeting by CEA‐targeted fluorescent imaging using
SGM‐101 was successful in both pancreatic and CRC patients.
A large phase III trial will soon be initiated in CRC patients.
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SYNOPSIS
SLN procedures for gastric cancer resections using ICG:Nanocoll outperformed normal ICG but did not provide information on possible lymph
node metastasis. CEA‐targeted fluorescent imaging using SGM‐101 was successful in both pancreatic and CRC.
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